Roberto Pili &ndash; Publications

Article

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature

Gotink, K. J., Broxterman, H. J., Honeywell, R. J., Dekker, H., de Haas, R. R., Miles, K. M., Adelaiye, R., Griffioen, A. W., Peters, G. J., Pili, R. & Verheul, H. M. W., 2014, In : Oncoscience. 1, 12, p. 844-853 10 p.

Research output: Contribution to journal › Article

Microvessels

Heterografts

Colonic Neoplasms

Neoplasms

sunitinib

5 Citations (Scopus)

Active ageing and success: A brief history of conceptual models

Petretto, D. R., Pili, R., Gaviano, L., Matos López, C. & Zuddas, C., Nov 28 2014, (Accepted/In press) In : Revista Espanola de Geriatria y Gerontologia.

Research output: Contribution to journal › Article

30 Citations (Scopus)

Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Pili, R., Hayat, H., Kovel, S., Sella, A., Boursi, B., Weitzen, R., Mermershtain, W., Rouvinov, K., Berger, R. & Carducci, M. A., 2014, In : Oncologist. 19, 1, p. 51-60 10 p.

Research output: Contribution to journal › Article

Renal Cell Carcinoma

Disease-Free Survival

Smoking

Survival

Hypertension

6 Citations (Scopus)

Adenovirus-mediated gene transfer of fibroblast growth factor-1: Angiogenesis and tumorigenicity in nude mice

Pili, R., Chang, J., Muhlhauser, J., Crystal, R. G., Capogrossi, M. C. & Passaniti, A., 1997, In : International Journal of Cancer. 73, 2, p. 258-263 6 p.

Research output: Contribution to journal › Article

Fibroblast Growth Factor 1

Adenoviridae

Nude Mice

Genes

Growth

60 Citations (Scopus)

Adenovirus‐mediated gene transfer of wild‐type p53 results in melanoma cell apoptosis in vitro and in vivo

Cirielli, C., Riccioni, T., Yang, C., Pili, R., Gloe, T., Chang, J., Inyaku, K., Passaniti, A. & Capogrossi, M. C., 1995, In : International Journal of Cancer. 63, 5, p. 673-679 7 p.

Research output: Contribution to journal › Article

Melanoma

Apoptosis

Genes

Neoplasms

DNA Fragmentation

257 Citations (Scopus)

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial

Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., Wilding, G., Cella, D., Wagner, L., Matin, S., Kuzel, T. M., Sexton, W. J., Wong, Y. N., Choueiri, T. K., Pili, R., Puzanov, I. & 5 others, Kohli, M., Stadler, W., Carducci, M., Coomes, R. & Dipaola, R. S., May 14 2016, In : The Lancet. 387, 10032, p. 2008-2016 9 p.

Research output: Contribution to journal › Article

Renal Cell Carcinoma

Placebos

sorafenib

sunitinib

Disease-Free Survival

1 Citation (Scopus)

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer

Wentink, M. Q., Broxterman, H. J., Lam, S. W., Boven, E., Walraven, M., Griffioen, A. W., Pili, R., Van Der Vliet, H. J., De Gruijl, T. D. & Verheul, H. M. W., Oct 11 2016, In : British Journal of Cancer. 115, 8, p. 940-948 9 p.

Research output: Contribution to journal › Article

Biological Assay

Vascular Endothelial Growth Factor A

Anti-Idiotypic Antibodies

Neoplasms

Therapeutics

47 Citations (Scopus)

A functional ryanodine-sensitive intracellular Ca²⁺ store is present in vascular endothelial cells

Ziegelstein, R. C., Spurgeon, H. A., Pili, R., Passaniti, A., Cheng, L., Corda, S., Lakatta, E. G. & Capogrossi, M. C., 1994, In : Circulation Research. 74, 1, p. 151-156 6 p.

Research output: Contribution to journal › Article

Ryanodine

Endothelial Cells

Bradykinin

Aorta

Buffers

11 Citations (Scopus)

A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma

Zhao, M., Rudek, M. A., Mnasakanyan, A., Hartke, C., Pili, R. & Baker, S. D., Jan 17 2007, In : Journal of Pharmaceutical and Biomedical Analysis. 43, 2, p. 784-787 4 p.

Research output: Contribution to journal › Article

Plasma (human)

formic acid

Liquid chromatography

Tandem Mass Spectrometry

Liquid Chromatography

10 Citations (Scopus)

Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma

Buck, M. J., Raaijmakers, L. M., Ramakrishnan, S., Wang, D., Valiyaparambil, S., Liu, S., Nowak, N. J. & Pili, R., Oct 9 2014, In : Oncogene. 33, 41, p. 4961-4965 5 p.

Research output: Contribution to journal › Article

DNA Methylation

Renal Cell Carcinoma

Formaldehyde

Chromatin

Neoplasms

107 Citations (Scopus)

Altered angiogenesis underlying age-dependent changes in tumor growth

Pili, R., Guo, Y., Chang, J., Nakanishi, H., Martin, G. R. & Passaniti, A., Sep 7 1994, In : Journal of the National Cancer Institute. 86, 17, p. 1303-1314 12 p.

Research output: Contribution to journal › Article

Angiogenesis

Tumor Growth

Tumors

Tumor

Dependent

46 Citations (Scopus)

Androgen Receptor Modulation Optimized for Response (ARMOR) phase i and II studies: Galeterone for the treatment of castration-resistant prostate cancer

Montgomery, B., Eisenberger, M. A., Rettig, M. B., Chu, F., Pili, R., Stephenson, J. J., Vogelzang, N. J., Koletsky, A. J., Nordquist, L. T., Edenfield, W. J., Mamlouk, K., Ferrante, K. J. & Taplin, M. E., Mar 15 2016, In : Clinical Cancer Research. 22, 6, p. 1356-1363 8 p.

Research output: Contribution to journal › Article

Castration

Androgen Receptors

Prostatic Neoplasms

Safety

Therapeutics

56 Citations (Scopus)

A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation

Lin, K. S., Luu, A., Baidoo, K. E., Hashemzadeh-Gargari, H., Chen, M. K., Brenneman, K., Pili, R., Pomper, M., Carducci, M. A. & Wagner, H. N., Jan 2005, In : Bioconjugate Chemistry. 16, 1, p. 43-50 8 p.

Research output: Contribution to journal › Article

Technetium

Bombesin

Peptides

Bombesin Receptors

Liver

19 Citations (Scopus)

A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier

Lin, K. S., Luu, A., Baidoo, K. E., Hashemzadeh-Gargari, H., Chen, M. K., Pili, R., Pomper, M., Carducci, M. & Wagner, H. N., Nov 2004, In : Bioconjugate Chemistry. 15, 6, p. 1416-1423 8 p.

Research output: Contribution to journal › Article

Technetium

Bombesin

Pharmacokinetics

Peptides

Bombesin Receptors

79 Citations (Scopus)

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination

Keizman, D., Huang, P., Eisenberger, M. A., Pili, R., Kim, J. J., Antonarakis, E. S., Hammers, H. & Carducci, M. A., Sep 2011, In : European Journal of Cancer. 47, 13, p. 1955-1961 7 p.

Research output: Contribution to journal › Article

Angiotensins

Renal Cell Carcinoma

Logistic Models

Survival

Angiotensin Receptor Antagonists

4 Citations (Scopus)

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

Pili, R., Carducci, M., Brown, P. & Hurwitz, H., Dec 1 2014, In : Investigational New Drugs. 32, 6, p. 1258-1268 11 p.

Research output: Contribution to journal › Article

Maximum Tolerated Dose

Protein-Tyrosine Kinases

Neoplasms

Neutropenia

Vascular Endothelial Growth Factor A

Antitumor activity and mechanistic characterization of APE1/ReF-1 inhibitors in bladder cancer

Fishel, M. L., Xia, H., McGeown, J., McIlwain, D. W., Elbanna, M., Craft, A. A., Kaimakliotis, H. Z., Sandusky, G. E., Zhang, C., Pili, R., Kelley, M. R. & Jerde, T. J., Jan 1 2019, In : Molecular cancer therapeutics. 18, 11, p. 1947-1960 14 p.

Research output: Contribution to journal › Article

Endonucleases

Urinary Bladder Neoplasms

Oxidation-Reduction

Cisplatin

Cell Proliferation

48 Citations (Scopus)

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

Qian, D. Z., Wei, Y. F., Wang, X., Kato, Y., Cheng, L. & Pili, R., Aug 1 2007, In : Prostate. 67, 11, p. 1182-1193 12 p.

Research output: Contribution to journal › Article

Histone Deacetylase Inhibitors

Prostatic Neoplasms

Acetylation

Growth

Histones

43 Citations (Scopus)

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

Kato, Y., Salumbides, B. C., Wang, X. F., Qian, D. Z., Williams, S., Wei, Y., Sanni, T. B., Atadja, P. & Pili, R., Jan 2007, In : Molecular Cancer Therapeutics. 6, 1, p. 70-81 12 p.

Research output: Contribution to journal › Article

NSC 153174

Isotretinoin

Histone Deacetylase Inhibitors

Melanoma

Tretinoin

26 Citations (Scopus)

A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer

Morris, M. J., Eisenberger, M. A., Pili, R., Denmeade, S. R., Rathkopf, D., Slovin, S. F., Farrelly, J., Chudow, J. J., Vincent, M., Scher, H. I. & Carducci, M. A., Oct 2012, In : Annals of Oncology. 23, 10, p. 2714-2719 6 p., mds078.

Research output: Contribution to journal › Article

Castration

Prostate

Prostatic Neoplasms

Stem Cells

Antigens

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

Michaelson, M. D., Gupta, S., Agarwal, N., Szmulewitz, R., Powles, T., Pili, R., Bruce, J. Y., Vaishampayan, U., Larkin, J., Rosbrook, B., Wang, E., Murphy, D., Wang, P., Lechuga, M. J., Valota, O. & Shepard, D. R., Jan 1 2019, In : Oncologist.

Research output: Contribution to journal › Article

Open Access

Renal Cell Carcinoma

Maximum Tolerated Dose

Neoplasms

Safety

Vascular Endothelial Growth Factor A

45 Citations (Scopus)

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

Pili, R., Qin, R., Flynn, P. J., Picus, J., Millward, M., Ho, W. M., Pitot, H., Tan, W., Miles, K. M., Erlichman, C. & Vaishampayan, U., Dec 2013, In : Clinical Genitourinary Cancer. 11, 4, p. 477-483 7 p.

Research output: Contribution to journal › Article

Vascular Endothelial Growth Factor Receptor

Protein-Tyrosine Kinases

Safety

Neoplasms

Carcinoma

53 Citations (Scopus)

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal ^® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

Harrison, M. R., Hahn, N. M., Pili, R., Oh, W. K., Hammers, H., Sweeney, C., Kim, K., Perlman, S., Arnott, J., Sidor, C., Wilding, G. & Liu, G., Dec 2011, In : Investigational New Drugs. 29, 6, p. 1465-1474 10 p.

Research output: Contribution to journal › Article

Nanoparticles

Prostatic Neoplasms

Medical Futility

Gastrointestinal Hemorrhage

Hyponatremia

46 Citations (Scopus)

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Bruce, J. Y., Eickhoff, J., Pili, R., Logan, T., Carducci, M., Arnott, J., Treston, A., Wilding, G. & Liu, G., Apr 2012, In : Investigational New Drugs. 30, 2, p. 794-802 9 p.

Research output: Contribution to journal › Article

Renal Cell Carcinoma

Nanoparticles

Disease Progression

2-methoxyestradiol

sunitinib

132 Citations (Scopus)

A Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

Heath, E. I., Hillman, D. W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., Gaskins, M., Pitot, H. C., Tan, W., Ivy, S. P., Pili, R., Carducci, M. A., Erlichman, C. & Liu, G., Dec 1 2008, In : Clinical Cancer Research. 14, 23, p. 7940-7946 7 p.

Research output: Contribution to journal › Article

tanespimycin

Prostatic Neoplasms

Prostate-Specific Antigen

Hormones

Fatigue

10 Citations (Scopus)

A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma

Sunkara, U., Walczak, J. R., Summerson, L., Rogers, T., Eisenberger, M., Denmeade, S., Pili, R., Huff, C. A., Sinibaldi, V. & Carducci, M. A., Jan 2004, In : Journal of Interferon and Cytokine Research. 24, 1, p. 37-41 5 p.

Research output: Contribution to journal › Article

temozolomide

Renal Cell Carcinoma

Interferons

Chills

Melanoma

1 Citation (Scopus)

A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone

Resta, L. P., Pili, R., Eisenberger, M. A., Spitz, A., King, S., Porter, J., Franke, A., Boinpally, R., Carducci, M. A. & Sweeney, C. J., Feb 2011, In : Cancer Chemotherapy and Pharmacology. 67, 2, p. 431-438 8 p.

Research output: Contribution to journal › Article

Mitoxantrone

Tumors

Neoplasms

Toxicity

Prednisone

A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])

Pili, R., Jegede, O., Carducci, M. A., Manola, J., Groteluschen, D. L., Appleman, L. L., Liu, G., Shanks, J. C., Dakhil, S. R., Dutcher, J. & DiPaola, R. S., Jan 5 2017, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journal › Article

Renal Cell Carcinoma

Disease Progression

Vascular Endothelial Growth Factor Receptor

aflibercept

Proteinuria

7 Citations (Scopus)

Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients

Bartoloni, C., Guidi, L., Pili, R., Lewis, Z. A., Tricerri, A., Cursi, F., Gentiloni, N., Cortesi, E. & Gambassi, G., 1993, In : Oncology. 50, 1, p. 27-34 8 p.

Research output: Contribution to journal › Article

Gastrointestinal Neoplasms

Antigen-Antibody Complex

Inflammatory Bowel Diseases

Immune Sera

Melanoma

32 Citations (Scopus)

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work

Armstrong, A. J., Kaboteh, R., Carducci, M. A., Damber, J. E., Stadler, W. M., Hansen, M., Edenbrandt, L., Forsberg, G., Nordle, Ö., Pili, R. & Morris, M. J., 2014, In : Urologic Oncology: Seminars and Original Investigations. 32, 8, p. 1308-1316 9 p.

Research output: Contribution to journal › Article

Castration

Prostatic Neoplasms

Randomized Controlled Trials

Placebos

Bone and Bones

42 Citations (Scopus)

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma

Keizman, D., Ish-Shalom, M., Pili, R., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Boursi, B., Maimon, N., Gottfried, M., Hayat, H., Peer, A., Kovel, S., Sella, A., Berger, R. & Carducci, M. A., May 2012, In : European Journal of Cancer. 48, 7, p. 1031-1037 7 p.

Research output: Contribution to journal › Article

Diphosphonates

Renal Cell Carcinoma

Disease-Free Survival

Neoplasm Metastasis

Bone and Bones

110 Citations (Scopus)

CEP-7055: A novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models

Ruggeri, B., Singh, J., Gingrich, D., Angeles, T., Albom, M., Chang, H., Robinson, C., Hunter, K., Dobrzanski, P., Jones-Bolin, S., Aimone, L., Klein-Szanto, A., Herbert, J. M., Bono, F., Schaeffer, P., Casellas, P., Bourie, B., Pili, R., Isaacs, J., Ator, M. & 4 others, Hudkins, R., Vaught, J., Mallamo, J. & Dionne, C., Sep 15 2003, In : Cancer Research. 63, 18, p. 5978-5991 14 p.

Research output: Contribution to journal › Article

Vascular Endothelial Growth Factor Receptor

Protein-Tyrosine Kinases

Vascular Endothelial Growth Factor A

Phosphotransferases

Nude Mice

19 Citations (Scopus)

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

Shen, L. & Pili, R., 2012, In : OncoImmunology. 1, 6, p. 948-950 3 p.

Research output: Contribution to journal › Article

Histone Deacetylase Inhibitors

Histone Deacetylases

Regulatory T-Lymphocytes

Immunotherapy

Immune Tolerance

82 Citations (Scopus)

Class I Histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K. M., Ellis, L., Sotomayor, P., Shrikant, P., Fenstermaker, R. & Pili, R., Jan 27 2012, In : PLoS One. 7, 1, e30815.

Research output: Contribution to journal › Article

kidney neoplasms

histone deacetylase

Histone Deacetylase Inhibitors

T-cells

Kidney Neoplasms

237 Citations (Scopus)

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α

Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P. & Pili, R., Sep 1 2006, In : Cancer Research. 66, 17, p. 8814-8821 8 p.

Research output: Contribution to journal › Article

Hypoxia-Inducible Factor 1

Histone Deacetylases

Histone Deacetylase Inhibitors

Transcriptional Activation

Proteins

29 Citations (Scopus)

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Radovich, M., Kiel, P. J., Nance, S. M., Niland, E. E., Parsley, M. E., Ferguson, M. E., Jiang, G., Ammakkanavar, N. R., Einhorn, L., Cheng, L., Nassiri, M., Davidson, D., Rushing, D. A., Loehrer, P., Pili, R., Hanna, N., Thomas Callaghan, J., Skaar, T., Helft, P., Shahda, S. & 2 others, O'Neil, B. H. & Schneider, B., 2016, In : Oncotarget. 7, 35, p. 56491-56500 10 p.

Research output: Contribution to journal › Article

Precision Medicine

Disease-Free Survival

Neoplasms

Therapeutics

Standard of Care

15 Citations (Scopus)

Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation

Wang, J., Papanicolau-Sengos, A., Chintala, S., Wei, L., Liu, B., Hu, Q., Miles, K. M., Conroy, J. M., Glenn, S. T., Costantini, M., Magi-Galluzzi, C., Signoretti, S., Choueiri, T., Gallucci, M., Sentinelli, S., Fazio, V. M., Poeta, M. L., Liu, S., Morrison, C. & Pili, R., May 24 2016, In : Oncotarget. 7, 21, p. 29901-29915 15 p.

Research output: Contribution to journal › Article

Renal Cell Carcinoma

Up-Regulation

Genes

Cisplatin

Single Nucleotide Polymorphism

11 Citations (Scopus)

Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells

Kato, Y., Yoshino, I., Egusa, C., Maeda, T., Pili, R. & Tsuboi, R., 2014, In : Journal of Dermatological Science. 75, 2, p. 140-147 8 p.

Research output: Contribution to journal › Article

Histone Deacetylase Inhibitors

T-cells

Interleukin-2

Tumors

Melanoma

114 Citations (Scopus)

Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis

Pili, R., Kruszewski, M. P., Hager, B. W., Lantz, J. & Carducci, M. A., Feb 15 2001, In : Cancer Research. 61, 4, p. 1477-1485 9 p.

Research output: Contribution to journal › Article

Phenylbutyrates

Isotretinoin

Prostate

Growth

Neoplasms

25 Citations (Scopus)

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial

Pili, R., Liu, G., Chintala, S., Verheul, H., Rehman, S., Attwood, K., Lodge, M. A., Wahl, R., Martin, J. I., Miles, K. M., Paesante, S., Adelaiye, R., Godoy, A., King, S., Zwiebel, J. & Carducci, M. A., Feb 21 2017, (Accepted/In press) In : British Journal of Cancer.

Research output: Contribution to journal › Article

Phase II Clinical Trials

Clinical Trials, Phase I

Histone Deacetylase Inhibitors

Renal Cell Carcinoma

Disease-Free Survival

94 Citations (Scopus)

Combination strategy targeting the hypoxia inducible factor-1 α with mammalian target of rapamycin and histone deacetylase inhibitors

Verheul, H. M. W., Salumbides, B., Van Erp, K., Hammers, H., Qian, D. Z., Sanni, T., Atadja, P. & Pili, R., Jun 1 2008, In : Clinical Cancer Research. 14, 11, p. 3589-3597 9 p.

Research output: Contribution to journal › Article

Hypoxia-Inducible Factor 1

Histone Deacetylase Inhibitors

Sirolimus

Human Umbilical Vein Endothelial Cells

Western Blotting

51 Citations (Scopus)

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

Ciamporcero, E., Miles, K. M., Adelaiye, R., Ramakrishnan, S., Shen, L., Ku, S. Y., Pizzimenti, S., Sennino, B., Barrera, G. & Pili, R., Jan 1 2015, In : Molecular Cancer Therapeutics. 14, 1, p. 101-110 10 p.

Research output: Contribution to journal › Article

Renal Cell Carcinoma

Vascular Endothelial Growth Factor A

Neoplasms

Therapeutics

Growth

44 Citations (Scopus)

Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer

Ellis, L., Ku, S. Y., Ramakrishnan, S., Lasorsa, E., Azabdaftari, G., Godoy, A. & Pili, R., Dec 2013, In : Oncotarget. 4, 12, p. 2225-2236 12 p.

Research output: Contribution to journal › Article

Histone Deacetylases

Androgen Receptors

Phosphatidylinositol 3-Kinases

Prostatic Neoplasms

DNA Damage

30 Citations (Scopus)

Concordance of cancer patients' function, symptoms, and supportive care needs

Snyder, C. F., Garrett-Mayer, E., Blackford, A. L., Brahmer, J. R., Carducci, M. A., Pili, R., Stearns, V., Wolff, A. C., Dy, S. M. & Wu, A. W., Oct 2009, In : Quality of Life Research. 18, 8, p. 991-998 8 p.

Research output: Contribution to journal › Article

Neoplasms

Observational Studies

Cross-Sectional Studies

14 Citations (Scopus)

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in MicroRNA expression

Ellis, L., Lehet, K., Ramakrishnan, S., Adelaiye, R., Miles, K. M., Wang, D., Liu, S., Atadja, P., Carducci, M. A. & Pili, R., Nov 7 2011, In : PLoS One. 6, 11, e27178.

Research output: Contribution to journal › Article

Histone Deacetylases

Androgen Receptors

MicroRNAs

microRNA

histones

39 Citations (Scopus)

Contrasting effects of sunitinib within in vivo models of metastasis

Welti, J. C., Powles, T., Foo, S., Gourlaouen, M., Preece, N., Foster, J., Frentzas, S., Bird, D., Sharpe, K., Weverwijk, A. V., Robertson, D., Soffe, J., Erler, J. T., Pili, R., Springer, C. J., Mather, S. J. & Reynolds, A. R., 2012, In : Angiogenesis. 15, 4, p. 623-641 19 p.

Research output: Contribution to journal › Article

Tumors

Neoplasm Metastasis

Neoplasms

Lung

Cells

17 Citations (Scopus)

Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer

Ciamporcero, E., Daga, M., Pizzimenti, S., Roetto, A., Dianzani, C., Compagnone, A., Palmieri, A., Ullio, C., Cangemi, L., Pili, R. & Barrera, G., Feb 1 2018, In : Free Radical Biology and Medicine. 115, p. 447-457 11 p.

Research output: Contribution to journal › Article

Crosstalk

Urinary Bladder Neoplasms

Antioxidants

Cells

Transcription Factors

3 Citations (Scopus)

Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer

Ramakrishnan, S., Hu, Q., Krishnan, N., Wang, D., Smit, E., Granger, V., Rak, M., Attwood, K., Johnson, C., Morrison, C., Pili, R., Chatta, G., Guru, K., Gueron, G., McNally, L., Wang, J. & Woloszynska-Read, A., Dec 1 2017, In : Cell Death and Disease. 8, 12, 3217.

Research output: Contribution to journal › Article

decitabine

Urinary Bladder Neoplasms

Interleukin-6

Muscles

DNA

9 Citations (Scopus)

Development of a castrate resistant transplant tumor model of prostate cancer

Ellis, L., Lehet, K., Ramakrishnan, S., Adelaiye, R. & Pili, R., May 1 2012, In : Prostate. 72, 6, p. 587-591 5 p.

Research output: Contribution to journal › Article

Prostatic Neoplasms

Transplants

Neoplasms

Androgens

Androgen Receptors

2 Citations (Scopus)

Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model

Affronti, H. C., Long, M. D., Rosario, S. R., Gillard, B. M., Karasik, E., Boerlin, C. S., Pellerite, A. J., Foster, B. A., Attwood, K., Pili, R., Wilton, J. H., Campbell, M. J. & Smiraglia, D. J., Jan 1 2017, In : Oncotarget. 8, 61, p. 103758-103774 17 p.

Research output: Contribution to journal › Article

Folic Acid

Prostatic Neoplasms

Recurrence

Androgens

Heterografts